Ferroptosis as a target for protection against cardiomyopathy

Xuexian Fang(Zhejiang University), Hao Wang(Zhengzhou University), Dan Han(Zhejiang University), Enjun Xie(Zhejiang University), Xiang Yang(Zhejiang University), Jiayu Wei(Zhejiang University), Shanshan Gu(Shanghai Jiao Tong University), Feng Gao(Second Affiliated Hospital of Zhejiang University), Nali Zhu(Institute of Biophysics), Xiangju Yin(Zhejiang University), Qi Cheng(Zhejiang University), Pan Zhang(Zhejiang University), Wei Dai(Zhejiang University), Jinghai Chen(Second Affiliated Hospital of Zhejiang University), Fuquan Yang(Institute of Biophysics), Huang‐Tian Yang(Shanghai Jiao Tong University), Andreas Linkermann(University Hospital Carl Gustav Carus), Wei Gu(Cancer Genetics (United States)), Junxia Min(Zhejiang University), Fudi Wang(Zhengzhou University)
Proceedings of the National Academy of Sciences
January 28, 2019
Cited by 2,108Open Access
Full Text

Abstract

-deficent mice. Conversely, zinc protoporphyrin IX, an Hmox1 antagonist, protected the DOX-treated mice, suggesting free iron released on heme degradation is necessary and sufficient to induce cardiac injury. Given that ferroptosis is driven by damage to lipid membranes, we further investigated and found that excess free iron accumulated in mitochondria and caused lipid peroxidation on its membrane. Mitochondria-targeted antioxidant MitoTEMPO significantly rescued DOX cardiomyopathy, supporting oxidative damage of mitochondria as a major mechanism in ferroptosis-induced heart damage. Importantly, ferrostatin-1 and iron chelation also ameliorated heart failure induced by both acute and chronic I/R in mice. These findings highlight that targeting ferroptosis serves as a cardioprotective strategy for cardiomyopathy prevention.


Related Papers

No related papers found

Powered by citation graph analysis